08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CC chemokine receptor 4 (CCR4; CD194) In vitro and mouse studies suggest anti-CCR4 mAbs could increase antitumor immunity by depleting a subset of Treg...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

GV1001: Phase III data

The open-label, U.K. Phase III TeloVac trial in 1,062 patients with advanced and metastatic pancreatic cancer showed that both concurrent and sequential administrations of GV1001 plus standard of care (SOC) of gemcitabine and capecitabine missed...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...
07:00 , May 13, 2013 |  BioCentury  |  Emerging Company Profile

Ultimovacs: hTERT redux

Ultimovacs AS is developing a telomerase-based cancer vaccine that could treat a broader range of cancer patients than the most advanced telomerase vaccine in the clinic by delivering multiple telomerase epitopes rather than a single...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Financial News

Affitech financial update

Trans Nova Investments agreed to extend the due date to Jan. 16, 2013, from Oct. 16 for its €1.5 million ($1.9 million) loan to Affitech. Affitech A/S , Copenhagen, Denmark   Business: Cancer, Infectious, Antibodies...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Financial News

Affitech financial update

Affitech said the Copenhagen Stock Exchange suspended delisting of the company. The Danish Financial Supervisory Authority (FSA) is considering whether the exchange's decision to remove Affitech from listing violates section 25 paragraph 3 of the...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Affitech cancer news

Affitech shareholder Trans Nova Investments Ltd. acquired 25.1 million shares in Affitech for DKK0.20 per share in cash, or DKK5 million ($846,038). The newly acquired shares represent a 5.14% stake. Trans Nova now owns about...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Affitech, Roche deal

Affitech received an undisclosed milestone payment from Roche under a May 2007 deal granting Roche rights to LC06, a human anti- angiopoietin 2 ( ANG2 ; ANGPT2 ) antibody. The payment follows completion of the...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Affitech cancer news

Affitech shareholder Trans Nova Investments Ltd. made a new offer to acquire the 28.7% of Affitech it does not already own for DKK0.20 per share in cash. Earlier this month, Affitech said NASDAQ OMX Copenhagen...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Financial News

Affitech completes debt financing

Affitech A/S (CSE:AFFI), Copenhagen, Denmark   Business: Cancer, Infectious, Antibodies   Date completed: 7/19/12   Type: Debt financing   Raised: €500,000 ($611,350)   Investor: Trans Nova Investments   Note: Affitech raised €500,000 ($611,350) in the...